Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells) / Northern Therap, MaxCyte, United Therapeutics Corp - LARVOL DELTA

SAPPHIRE: Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension (clinicaltrials.gov) - P2/3 | N=22 | Terminated | Sponsor: Northern Therapeutics | N=12 ➔ 22 | Active, not recruiting ➔ Terminated; Lower than anticipated enrollment

Enrollment change • Trial termination • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

SAPPHIRE: Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs (clinicaltrials.gov) - P2/3 | N=12 | Active, not recruiting | Sponsor: Northern Therapeutics | Trial completion date: Dec 2023 ➔ Dec 2033

Trial completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

SAPPHIRE: Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs (clinicaltrials.gov) - P2/3 | N=12 | Active, not recruiting | Sponsor: Northern Therapeutics | Recruiting ➔ Active, not recruiting | N=45 ➔ 12 | Trial completion date: Dec 2025 ➔ Dec 2023 | Trial primary completion date: Dec 2025 ➔ Dec 2023

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Solid Tumor